Investors

    NASDAQ: STEM

      Listed on the NASDAQ Market since 1992, we are committed to       balancing our standards of scientific rigor and clinical integrity with our       corporate imperatives of value creation and long-term business       sustainability.

Corporate Profile

Driven by nearly 20 years of pioneering research and innovation, StemCells, Inc. is at the forefront of a breakthrough approach to treating human disease. We are applying our scientific and industry leadership in stem cell biology to discover, develop and commercialize novel therapeutics and enabling tools and technologies for use in stem cell-based research and drug discovery.
More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
CEO Podcast
10/15/2014  Martin McGlynn Interview on BioTech Nation Radio
Letter to Investors
May 2014  Letter to Investors from CEO Martin McGlynn
Recent News
12/18/14StemCells, Inc. Transplants First Participant in Phase II Clinical Trial in Cervical Spinal Cord Injury
Pathway Study to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., Dec. 18, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, announced today that it has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform techn... 
Printer Friendly Version
12/02/14StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
NEWARK, Calif., Dec. 2, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leader in the development of cell-based therapies for disorders of the central nervous system (CNS), hosted its first investor and analyst event in New York, on November 20, 2014. The event was well-attended by biotech investing VIPs including representatives from Maxim Group, Piper Jaffray, Brinson Patrick Securities, Needham and Company, H.C. Wainwright and Company, Cantor Fitzgerald, Ladenburg Thalmann and M... 
Printer Friendly Version
11/20/14StemCells, Inc. to Host Inaugural Investor and Analyst Event in New York
NEWARK, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), who pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, will host its first investor and analyst event today, November 20, 2014, in New York. The program will feature a keynote address from Irving L. Weissman M... 
Printer Friendly Version
11/05/14StemCells, Inc. Reports Third Quarter 2014 Financial and Operating Results
StemCells, Inc. to Host Investor and Analyst Event in New York, November 20, 2014 NEWARK, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), which pioneered the discovery and development of HuCNS-SC® cells, a proprietary population of highly purified, expandable human neural stem cells and is leading the development of cell based therapies for the treatment of disorders of the central nervous system, today reported financial results for the third quarter ended September 30,... 
Printer Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.96
Change (%) Stock is Down 0.03 (3.03%)
Volume558,268
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet